RxDoctor Payments Data

Kris Storkersen, MD

Ophthalmology · Colton, CANPI 1154438935

Payments from drug & device makers

$3,408in general payments, 2019–2025

Across 196 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Dompe US, Inc.$561
  • Aerie Pharmaceuticals, Inc.$448
  • Amgen$417
  • Alcon$307
  • Sight Sciences, Inc.$99
  • plus $433 from 10 others

What the payments were for

  • Food & beverage$3,33898%
  • Education$702%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,408 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$227,140
Medicare patients
660
Services billed
2,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine228$64,724
RhopressaNetarsudil Mesylate131$61,361
RestasisCyclosporine86$52,448
Restasis MultidoseCyclosporine55$36,279
Brimonidine Tartrate601$34,602
LumiganBimatoprost40$24,852
XiidraLifitegrast27$19,628
Latanoprost1,865$17,439
Alphagan PBrimonidine Tartrate51$13,336
RocklatanNetarsudil Mesylat/Latanoprost24$10,217
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat612$10,130
Prednisolone Acetate266$7,769
Travoprost55$6,866
Ketorolac Tromethamine136$5,758
Timolol Maleate425$4,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Lumigan, Alphagan P$1,142$126,915232 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$448$71,578155 claims
Bausch & Lomb Americas Inc.Xiidra$37$19,62827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →